Publicacións en colaboración con investigadores/as de Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (76)

2024

  1. A Genome-Wide Association Study of Respiratory Syncytial Virus Infection Severity in Infants

    Journal of Infectious Diseases, Vol. 229, pp. S112-S119

  2. A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

    Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

  3. Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol

    Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

  4. COVID-19 InfoVaccines: A WHO-supported educational project to promote COVID-19 vaccination information among professionals and the general population

    Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

  5. Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule

    Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

  6. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study

    The Lancet Infectious Diseases

  7. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 78, Núm. 6, pp. 1732-1744

  8. Erratum to «Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper» [Arch Bronconeumol. 2024;60(3):161–170] (Archivos de Bronconeumología (2024) 60(3) (161–170), (S0300289624000061), (10.1016/j.arbres.2024.01.004))

    Archivos de Bronconeumologia

  9. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

    The Journal of experimental medicine, Vol. 221, Núm. 2

  10. How Does the Burden of Respiratory Syncytial Virus Compare to Influenza in Spanish Adults?

    Influenza and other Respiratory Viruses, Vol. 18, Núm. 6

  11. Multi-tissue transcriptomics of a unique monozygotic discordant twin case of severe progressive osseous heteroplasia

    Genes and Diseases, Vol. 11, Núm. 3

  12. Mycoplasma pneumoniae at the rise not only in China: rapid increase of Mycoplasma pneumoniae cases also in Spain

    Emerging Microbes and Infections

  13. New Vaccines for Chronic Respiratory Patients

    Archivos de Bronconeumologia

  14. Plasma Protein Biomarkers Distinguish Multisystem Inflammatory Syndrome in Children From Other Pediatric Infectious and Inflammatory Diseases

    The Pediatric infectious disease journal, Vol. 43, Núm. 5, pp. 444-453

  15. Respiratory Syncytial Virus Vaccination Recommendations for Adults Aged 60 Years and Older: The NeumoExperts Prevention Group Position Paper

    Archivos de Bronconeumologia, Vol. 60, Núm. 3, pp. 161-170

  16. Short- and mid-term morbidity and primary-care burden due to infant respiratory syncytial virus infection: A Spanish 6-year population-based longitudinal study

    Pediatric Allergy and Immunology, Vol. 35, Núm. 5

  17. Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019-2023)

    Journal of Infection, Vol. 89, Núm. 2

  18. Targeted metagenomics reveals association between severity and pathogen co-detection in infants with respiratory syncytial virus

    Nature Communications, Vol. 15, Núm. 1

2023

  1. A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)

    Vaccine, Vol. 41, Núm. 21, pp. 3387-3398

  2. Addressing influenza’s underestimated burden – Iberian experts call to action

    BMC Infectious Diseases